Protective effect of intranasal regimens containing peptidic middle east respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection

Journal of Infectious Diseases

Volumn 212, Issue 12, 2015, Pages 1894-1903

  Channappanavar, Rudragouda ^a   Lu, Lu ^b   Xia, Shuai ^b   Du, Lanying ^c   Meyerholz, David K ^a   Perlman, Stanley ^a   Jiang, Shibo ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

Fusion inhibitor; Interferon; MERS CoV; Peptide

Indexed keywords

BETA INTERFERON; DIPEPTIDYL PEPTIDASE IV; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS FUSION INHIBITOR; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; VITRONECTIN; ANTIVIRUS AGENT; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUSION; CONTROLLED STUDY; CORONAVIRUS INFECTION; FAMILY; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN; ANIMAL; C57BL MOUSE; CELL LINE; CORONAVIRUS INFECTIONS; DISEASE MODEL; DRUG EFFECTS; HUMAN; INTRANASAL DRUG ADMINISTRATION; PHYSIOLOGY; VIROLOGY; VIRUS ENTRY; VIRUS LOAD;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; MICE, INBRED C57BL; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PEPTIDES; VIRAL LOAD; VIRUS INTERNALIZATION;

EID: 84953874422     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv325     Document Type: Article

References (40)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20.
2. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407-16.
3. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome corona-virus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013; 15:625-9.
4. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome co-ronavirus infections in health care workers. N Engl J Med 2013; 368:2487-94.
5. Adney DR, van DN, Brown VR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 2014; 20:1999-2005.
6. Gossner C, Danielson N, Gervelmeyer A, et al. Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection. Zoonoses Public Health 2014; doi:10.1111/zph.12171.
7. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19:1819-23.
8. Reuss A, Litterst A, Drosten C, et al. Contact investigation for imported case of Middle East respiratory syndrome, Germany. Emerg Infect Dis 2014; 20:620-5.
9. Perlman S, McCray PB Jr. Person-to-person spread of the MERS coro-navirus-an evolving picture. N Engl J Med 2013; 369:466-7.
10. Chen Y, Rajashankar KR, Yang Y, et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 2013; 87:10777-83.
11. Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87:9939-42.
12. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-31.
13. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new MERS coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013; 87:9379-83.
14. Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23:986-93.
15. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4.
16. Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5:3067.
17. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-73.
18. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365:113.
19. Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004; 363:938-47.
20. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Pep-tides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91:9770-4.
21. Chen YH, Yang JT, Chau KH. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry 1974; 13:3350-9.
22. Liu S, Zhao Q, Jiang S. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 2003; 24:1303-13.
23. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2:1075-82.
24. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81.
25. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005; 174:4908-15.
26. Zhao G, Du L, Ma C, et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J 2013; 10:266.
27. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111:4970-5.
28. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282:1-23.
29. MERS-coronavirus sequence acknowledgements. 2014. http://epidemic. bio.ed.ac.uk/MERS-sequences. Accessed 23 May 2015.
30. Cotten M, Watson SJ, Zumla AI, et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio 2014; 5: e01062-13.
31. Cockrell AS, Peck KM, Yount BL, et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome corona-virus infection. J Virol 2014; 88:5195-9.
32. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvir-tide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005; 49:1113-9.
33. Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome corona-virus in cell-based assays. J Gen Virol 2014; 95:571-7.
34. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-[alpha]2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313-7.
35. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20:42-6.
36. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875-84.
37. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory coronavirus infection. Antimicrob Agents Chemother 2014; 58:4885-93.
38. Liu Q, Xia S, Sun Z, et al. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother 2015; 59:742-4.
39. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606-16.
40. Zielecki F, Weber M, Eickmann M, et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to SARS-coronavirus. J Virol 2013; 87:5300-4.